

## Press release

# IBA considers private placement of shares in the United States

For immediate release – December 3, 2001

**Louvain-la-Neuve, Belgium, December 3, 2001** – Ion Beam Applications S.A. (“IBA”) confirmed today that it is considering to offer shares in a private placement to institutional investors primarily in the United States (pursuant to the exemption of Rule 144A under the U.S. Securities Act of 1933).

Today, IBA achieves two thirds of its revenues in the United States. Given its further expansion plans in FDG/PET, Proton Therapy, Brachytherapy, food and mail safety, adding prominent US institutional investors to its current shareholders’ base is expected to provide greater visibility and momentum to its U.S. operations. This would also facilitate longer term access to the U.S. capital markets.

IBA has retained Bear, Stearns International Limited as the placement agent to offer and sell shares in the private placement. The number of shares, price and other specific terms of the proposed transaction have not been finalized. A limited number of existing shares held by Belgian Anchorage would be part of the offering.

### About IBA

With more than 1500 employees at 49 sites in 12 countries on 3 continents, IBA ([www.iba-worldwide.com](http://www.iba-worldwide.com)) is a recognized world leader in both its industrial markets (Sterilization & Ionization) and medical markets (Advanced Radiotherapy, Radioisotopes & Brachytherapy).

By leveraging its unique expertise in particle accelerator technology, advanced physics and chemistry, IBA continues to fulfill its worldwide mission, that of providing high-value innovative solutions in the areas of health and well-being.

**This announcement and the information contained herein is not for distribution in the United States, Canada, Australia and Japan. It is not an offer of securities for sale in the United States, Canada, Australia or Japan.**

**The shares the subject of the proposed private placement have not been and will not be registered under the U.S. Securities Act of 1933 and may not be offered or sold in the United States or to, or for the account or benefit of, U.S. persons (as such terms are defined in Regulation S under the U.S. Securities Act of 1933 as amended) absent registration or an exemption from registration. No public offering of the shares will be made in the United States.**

For more information, contact:

IBA Headquarters Belgium

Vivienne Gaskell, Vice President, Corporate Communications

## Press release

Tel: +10/475971; e-mail: [gaskell@iba.be](mailto:gaskell@iba.be).